CONCOMITANT USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND PROTON PUMP INHIBITORS (PPIS) IN NEWLY DIAGNOSED PATIENTS WITH OSTEOARTHRITIS (OA), RHEUMATOID ARTHRITIS (RA) OR ANKYLOSING SPONDYLITIS (AS)
Author(s)
Dziarmaga A1, Reidel K2, White R1, Tarride J1, Corner N2
1AstraZeneca Canada Inc., Mississauga, ON, Canada, 2IMS Brogan Canada, Kirkland, QC, Canada
OBJECTIVES: The use of PPIs to reduce the risk of upper GI events caused by NSAIDs is well documented. The aim of this study was to understand whether newly diagnosed patients with OA, RA or AS not previously exposed to PPIs, receive a gastro-protectant with their NSAID treatment at initiation or follow up in a primary care setting. METHODS: We analyzed data from primary care Electronic Medical Records in Ontario, Canada. Patients ≥18 years, who were new users of NSAIDs, NSAID plus a PPI, a fixed combination of diclofenac and misoprostol, or Celecoxib between January 1st
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PMS96
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Musculoskeletal Disorders